The TFRI-MOHCCN Technology Development Awards provides funding to projects to develop additional profiling technologies that would generate data compatible with precision oncology and could be applied to a section of the MOHCCN Gold Cohort.
When autocomplete results are available use up and down arrows to review and enter to select.
Characterizing genomic signatures in predicting renal cell carcinoma therapy response
Aim/goals:
To characterize genomic backgrounds of responders’ vs non-responders to current immunotherapies for renal cell carcinoma
Summary:
Immunotherapy is the main stay of treatment for renal cell carcinoma. However, to date, clinicians cannot predict which patients may respond or be refractory to treatment. The aim of this project is to characterize genomic backgrounds and biomarkers that could infer response vs resistant to such therapies